These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 14521494)

  • 1. Gatifloxacin in community-acquired respiratory tract infection.
    Sethi S
    Expert Opin Pharmacother; 2003 Oct; 4(10):1847-55. PubMed ID: 14521494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety.
    Bhavnani SM; Andes DR
    Pharmacotherapy; 2005 May; 25(5):717-40. PubMed ID: 15899734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of the fluoroquinolones: focus on respiratory infections.
    Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
    Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA; Ehrhardt AF; Jones RN
    Am J Med; 2001 Dec; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections.
    File TM; Tillotson GS
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):831-43. PubMed ID: 15566328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of New Fluoroquinolones : Focus on their Use in Respiratory Tract Infections.
    Zhanel GG; Fontaine S; Adam H; Schurek K; Mayer M; Noreddin AM; Gin AS; Rubinstein E; Hoban DJ
    Treat Respir Med; 2006; 5(6):437-65. PubMed ID: 17154673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.
    Van Wart S; Phillips L; Ludwig EA; Russo R; Gajjar DA; Bello A; Ambrose PG; Costanzo C; Grasela TH; Echols R; Grasela DM
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4766-77. PubMed ID: 15561855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
    Nicholson SC; High KP; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):109-16. PubMed ID: 12376040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gatifloxacin, an advanced 8-methoxy fluoroquinolone.
    Fish DN; North DS
    Pharmacotherapy; 2001 Jan; 21(1):35-59. PubMed ID: 11191737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin.
    Medeiros EA
    Braz J Infect Dis; 2002 Aug; 6(4):149-56. PubMed ID: 12204181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.
    Keam SJ; Croom KF; Keating GM
    Drugs; 2005; 65(5):695-724. PubMed ID: 15748100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
    Nicholson SC; Webb CD; Andriole VT; Jones RN; Wilson WR
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):101-7. PubMed ID: 12376039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of gemifloxacin in the management of community-acquired lower respiratory tract infections.
    Blondeau JM; Tillotson G
    Int J Antimicrob Agents; 2008 Apr; 31(4):299-306. PubMed ID: 18276120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.
    Shams WE; Evans ME
    Drugs; 2005; 65(7):949-91. PubMed ID: 15892589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.
    Croom KF; Goa KL
    Drugs; 2003; 63(24):2769-802. PubMed ID: 14664657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.